Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nutriband Inc WT (NQ: NTRBW )

1.240 -0.010 (-0.80%)
Streaming Delayed Price Updated: 3:01 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,850
Open 1.250
Bid (Size) 0.6500 (10)
Ask (Size) 2.000 (10)
Prev. Close 1.250
Today's Range 1.240 - 1.390
52wk Range 0.1885 - 3.440
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire

Performance

YTD
+313.47%
+313.47%
1 Month
+30.53%
+30.53%
3 Month
N/A
N/A
6 Month
+75.49%
+75.49%
1 Year
+148.00%
+148.00%

More News

Read More
Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors
Via ACCESSWIRE
Nutriband Inc. Announces $8.4M Private Placement
Via ACCESSWIRE
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st
Via ACCESSWIRE
NUTRIBAND RECEIVES CHINA PATENT NOTICE OF ALLOWANCE FOR ITS AVERSA™ ABUSE DETERRENT TRANSDERMAL TECHNOLOGY
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
Via ACCESSWIRE
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
Via ACCESSWIRE
Nutriband Inc. Authorizes $1M Share Buyback Program
Via ACCESSWIRE
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
Via ACCESSWIRE
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25
Via ACCESSWIRE
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
Via ACCESSWIRE
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
Via ACCESSWIRE
Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year
Via ACCESSWIRE
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission
Via ACCESSWIRE
Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group
Via ACCESSWIRE
Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance
Via ACCESSWIRE
Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch
Via ACCESSWIRE
Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting
Via ACCESSWIRE
Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting
Via ACCESSWIRE
Nutriband CEO Publishes Letter to Shareholders
Via ACCESSWIRE
Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
Via ACCESSWIRE
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling
Via ACCESSWIRE
Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
Via ACCESSWIRE
Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales 0f $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.